World's Best Scientists 2026 revealed!
Filippo de Braud

Filippo de Braud

D-Index & Metrics

Medicine

D-Index
103
Citations
55300
World Ranking
7203
National Ranking
239

Overview

Filippo de Braud is affiliated with the University of Milan in Italy. Their work primarily spans the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a focus on various subfields related to cancer and respiratory medicine.

Their research covers Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology, and Surgery. This interdisciplinary approach supports investigations into cancer mechanisms, treatments, and diagnostics.

Filippo de Braud's main topics of study include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Lung Cancer Research Studies
  • Pancreatic and Hepatic Oncology Research

Their published papers include:

  • Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer, 2020, New England Journal of Medicine
  • Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial, 2020, The Lancet Oncology
  • Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies, 2020, International Journal of Cancer
  • Caring for patients with cancer in the COVID-19 era, 2020, Nature Medicine
  • Fasting-mimicking diet and hormone therapy induce breast cancer regression, 2020, Nature

Filippo de Braud frequently publishes in leading journals such as:

  • Annals of Oncology
  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • ESMO Open
  • Cancer Research

The scientist collaborates regularly with several co-authors, including Claudia Proto, Giuseppe Lo Russo, Federico Nichetti, Giancarlo Pruneri, and Marta Brambilla. These collaborations encompass numerous joint publications, reflecting a consistent network of research partnerships.

Best Publications

  • Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

    A. de Gramont;A. Figer;M. Seymour;M. Homerin

  • Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer

    Carsten Bokemeyer;Igor Bondarenko;Anatoly Makhson;Joerg T. Hartmann

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

    Scott J. Antonia;José A. López-Martin;Johanna Bendell;Patrick A. Ott

  • Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

    C. Bokemeyer;I. Bondarenko;J. T. Hartmann;F. de Braud

  • Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer

    Daniel G. Haller;Josep Tabernero;Jean Maroun;Filippo De Braud

  • Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).

    Alexander Drilon;Salvatore Siena;Sai Hong Ignatius Ou;Manish Patel

  • Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

    Padmanee Sharma;Margaret K. Callahan;Petri Bono;Joseph Kim

  • Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

    Yuchen Jiao;Timothy M Pawlik;Robert A Anders;Florin M Selaru

  • Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

    G. V. Long;K. T. Flaherty;D. Stroyakovskiy;H. Gogas

  • Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Drilon;Geoffrey R. Oxnard;Daniel S.W. Tan;Herbert H.F. Loong

  • Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

    M. Colleoni;A. Rocca;M. T. Sandri;L. Zorzino

  • Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth

    Giovanni Germano;Simona Lamba;Giuseppe Rospo;Ludovic Barault

  • Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

    Filippo Pietrantonio;Fausto Petrelli;Andrea Coinu;Maria Di Bartolomeo

  • CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

    Yelena Y. Janjigian;Johanna Bendell;Emiliano Calvo;Joseph W. Kim

  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

    Sung-Bae Kim;Rebecca Dent;Seock-Ah Im;Marc Espié

  • Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

    Alexander Drilon;Alexander Drilon;Salvatore Siena;Rafal Dziadziuszko;Fabrice Barlesi

  • Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.

    Vivek Subbiah;Ulrik Lassen;Elena Élez;Antoine Italiano

  • Totally implantable central venous access ports for long-term chemotherapy : a prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days

    R. Biffi;F. de Braud;F. Orsi;S. Pozzi

Frequent Co-Authors

Marina Chiara Garassino
Marina Chiara Garassino University of Chicago
Giuseppe Curigliano
Giuseppe Curigliano University of Milan
Giuseppe Pelosi
Giuseppe Pelosi University of Milan
Luigi Mariani
Luigi Mariani University Hospital of Basel
Alfredo Falcone
Alfredo Falcone University of Pisa
Sara Lonardi
Sara Lonardi Istituto Oncologico Veneto
Vincenzo Mazzaferro
Vincenzo Mazzaferro University of Milan
Giancarlo Pruneri
Giancarlo Pruneri University of Milan
Salvatore Siena
Salvatore Siena University of Milan
Maria Grazia Daidone
Maria Grazia Daidone University of Milan

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always have to follow the traditional path. There are a variety of related online degrees and career pathways that offer flexibility and unique opportunities for professional growth, often helping you enter the healthcare field faster or specialize in high-demand areas.

For those interested in nursing but concerned about rigorous entrance exams, there are lpn program no entrance exam options available, making the entry process more accessible. If you’re aiming for a leadership role, consider an accelerated healthcare administration degree online to quickly build the necessary management skills.

Registered nurses seeking career advancement can bridge their education with adn to np programs online, moving efficiently toward nurse practitioner roles. Meanwhile, those passionate about wellness and nutrition can study from anywhere with a nutrition bachelor degree online.

Each of these educational routes can complement or provide alternatives to traditional medical education, helping you tailor your career in a way that fits your goals and lifestyle.

Best Scientists Citing Filippo de Braud

Trending Scientists